CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $11M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Holders
20
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$4.35M | |
| 2 | +$327K | |
| 3 | +$257K | |
| 4 |
LPL Financial
San Diego,
California
|
+$195K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$23.7K |
Top Sellers
| 1 | -$658K | |
| 2 | -$304K | |
| 3 | -$236K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$186K |
| 5 |
CA
CoreCap Advisors
Southfield,
Michigan
|
-$121K |